Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the treatment strategy of long-term
intermittent every 30 days, continuous intravenous infusion for 24 hours of Levosimendan,
associated to optimal contemporary treatment for advanced heart failure reduce the incidence
of admission for heart failure worsening at 12 months follow up, compared with the strategy
based solely in the optimal contemporary treatment for advanced heart failure.